CD46 | ApexOnco - Clinical Trials news and analysis

x

“It's very intuitive and always up-to-date”

Monika Vogelmann

Head of Market Insights Oncology Europe

Daiichi Sankyo

Click here for more information

Trial results

31 July 2024

FibroGen finally walks away from pamrevlumab

Interviews

24 April 2024

FibroGen throws down the prostate cancer gauntlet

Amid doubts about early data with FG-3246, the group is scathing about its rivals.

Subscribe to CD46